Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for Migraine in Adults

 Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for Migraine in Adults

Teva Reports Results of Fremanezumab in P-IIIb FOCUS Study for Migraine in Adults

Shots:

  • The P-IIIb FOCUS study involves assessing of fremanezumab (quarterly & monthly) vs PBO in patients in a ratio (1:1:1) with episodic/chronic migraine (EM/CM) prior treated with two to four classes of preventive therapy
  • The P-IIIb FOCUS study results: @3mos. reduction in monthly migraine days; reduction in migraine-related symptoms; improvement in disability & QOL; improvements in depression status; work productivity and activity impairment
  • Fremanezumab (TEV-48125) is a mAb targeting CGRP, thus preventing its binding to receptors and has received approval in the US & EU on Sept’2018 & Apr’2019 respectively

Click here to read full press release/ article | Ref: Teva | Image:  Rasayanika

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post